JPMorgan raised the firm’s price target on Neurocrine to $173 from $169 and keeps an Overweight rating on the shares. The analyst says the Phase 2 data for NBI-1117568 in schizophrenia is expected in Q3. In a win scenario, the firm sees fundamental upside in the $15-$20 share range versus sentiment driven downside in the mid-single digits percentage range on a setback or if the program is discontinued.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine announces FDA accepted two NDAs
- Neurocrine presented CAHtalyst Phase 3 studies at ENDO 2024
- Neurocrine announces CAHtalyst Pediatric Phase 3 study met primary endpoint
- Neurocrine announces CAHtalyst Phase 3 study met primary endpoint
- Neurocrine Biosciences Announces CEO Retirement and Succession